Showing results (261-270 of 283) with videos related to
Sort By:
Pageof 29
Proceedings of the National Academy of Sciences of the United States of America|July 25, 2022
IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancerLi-Teng Ong, Wee Chyan Lee, Shijun Ma, et al.NPJ Breast Cancer|January 5, 2021
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefitSanne Løkkegaard, Daniel Elias, Carla L Alves, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2015
Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non-Small Cell Lung CancerTom Donnem, Sigurd M Hald, Erna-Elise Paulsen, et al.Journal of Experimental & Clinical Cancer Research : CR|January 23, 2025
Stochastic demethylation and redundant epigenetic suppressive mechanisms generate highly heterogeneous responses to pharmacological DNA methyltransferase inhibitionMie K Jakobsen, Sofie Traynor, Aaraby Y Nielsen, et al.Journal of Experimental & Clinical Cancer Research : CR|August 18, 2025
JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancerSarah Alexandrou, Christine S Lee, Kristine J Fernandez, et al.Cancer & Metabolism|June 6, 2019
Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHCGro V Røsland, Sissel E Dyrstad, Deusdedit Tusubira, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19Maria Ormhøj, Irene Scarfò, Maria L Cabral, et al.Ebiomedicine|April 13, 2023
Macrophage CD5L is a target for cancer immunotherapyLidia Sanchez-Moral, Tony Paul, Clara Martori, et al.Breast Cancer Research and Treatment|May 4, 2015
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialBrian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.Nature Medicine|October 3, 2017
Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrenceJian Yuan Goh, Min Feng, Wenyu Wang, et al.Pageof 29